大气压等离子体
肺癌
材料科学
信号转导
癌症研究
纳米颗粒
等离子体
癌症治疗
癌症
纳米技术
医学
化学
内科学
生物化学
物理
量子力学
作者
Yueye Huang,Rui Zhang,Xiao Chen,Fei Cao,Qiujie Fang,Qingnan Xu,Shicong Huang,Yufan Wang,Guojun Chen,Zhitong Chen
标识
DOI:10.1109/trpms.2025.3576730
摘要
Despite advancements in lung cancer therapy, the prognosis for advanced or metastatic patients remains poor, yet many patients eventually develop resistance to standard treatments leading to disease progression and poor survival. Here, we described a combination of CAP (Cold Atmosphere plasma) and nanoparticles (ZrO2 NPs (zirconium oxide nanoparticle) and 3Y-TZP NPs (3% mol Yttria Tetragonal Zirconia Polycrystal Nanoparticle)) for lung cancer therapy. We found that ZrO2 NPs caused obvious damage to the inside of the lung cancer cells. CAP and ZrO2 NPs mainly affected the mitochondria function, leading to a decrease in mitochondrial membrane potential and ATP levels, also causing endoplasmic reticulum stress and cell nucleus internal DNA damage, etc. CAP combined with ZrO2 NPs (CAP@ZrO2) induced lung cancer cell apoptosis by activating the TGFβ pathway. However, 3Y-TZP NPs showed beneficial effects for cancer cells, promoting their proliferation. This contrasting finding highlights that not all zirconia nanoparticles may be appropriate for lung cancer treatment in general. CAP@ZrO2 offers a new therapy for the clinical treatment of lung cancer
科研通智能强力驱动
Strongly Powered by AbleSci AI